MCOLN2

MCOLN2/TRPML2 is a constitutively active, inwardly rectifying, non-selective cation channel that resides primarily on recycling endosomes and lysosomes of immune cells, where it conducts Ca²⁺, Na⁺, Fe²⁺, and Mg²⁺ to regulate endolysosomal trafficking, chemokine secretion, and innate immune defense. The channel assembles as a homotetramer and can heterodimerize with TRPML1 and TRPML3, which determines its subcellular targeting; its activity is gated by luminal pH through a Ca²⁺-binding pre-pore loop in the extracytosolic domain and by phosphoinositide-dependent mechanosensitivity that accelerates endosomal recycling (PMID:16606612, PMID:19940139, PMID:31178222, PMID:33177082). Transcriptionally activated by PAX5 and upregulated by TLR signaling, TRPML2 directly mediates CCL2 chemokine trafficking and secretion from macrophages and conducts Mg²⁺ out of endolysosomes to restrict intracellular Salmonella Typhi replication as a component of nutritional immunity (PMID:25445271, PMID:26432893, PMID:30479274, PMID:37228749). Sphingomyelin accumulation in the lysosomal membrane inhibits TRPML2-mediated Ca²⁺ release, sensitizing lysosomes to membrane permeabilization, while TRPML2 activation can also engage the IL-1β/NF-κB signaling axis (PMID:34548638, PMID:41634107).

1. 2006 High

   Establishing that TRPML2 forms homo- and heteromultimers with TRPML1 and TRPML3 answered the fundamental question of channel quaternary structure and revealed a hierarchy in which TRPML1/2 direct TRPML3 localization to lysosomes, placing TRPML2 in the endolysosomal compartment.

   Evidence Reciprocal co-immunoprecipitation and co-expression localization studies with immunofluorescence in heterologous cells

   PMID:16606612

   Open questions at the time

   • Stoichiometry of heteromultimers not determined
   • Endogenous heteromultimerization not confirmed in primary cells
   • Functional consequence of heteromultimerization on channel conductance unknown
2. 2009 High

   Demonstrating that TRPML2 is a constitutively active, inwardly rectifying, non-selective cation channel inhibited by low extracytosolic pH established its core biophysical identity and separated it functionally from TRPML1 and TRPML3.

   Evidence Whole-cell patch-clamp electrophysiology with functional mutagenesis and cell death assays; complemented by transcriptional regulation showing TRPML1 controls TRPML2 short-variant expression

   PMID:19763610 PMID:19940139

   Open questions at the time

   • Endogenous single-channel conductance not measured
   • Physiological role of constitutive activity unclear
   • Mechanism by which low pH inhibits channel gating not structurally resolved
3. 2014 Medium

   Identification of PAX5 as the transcriptional activator of MCOLN2 explained the gene's lymphoid-restricted expression pattern and mapped the core promoter element to a specific 20-bp region upstream of the TSS.

   Evidence Dual-luciferase reporter assay with promoter mutagenesis, PAX5 overexpression and RNAi in cell lines

   PMID:25445271

   Open questions at the time

   • ChIP-seq validation of PAX5 occupancy at the endogenous MCOLN2 promoter not shown
   • Whether additional transcription factors cooperate with PAX5 not addressed
   • Regulation in non-lymphoid immune cells (macrophages) not explained by PAX5 alone
4. 2015 High

   Genetic knockout in mice revealed that TRPML2 localizes to recycling endosomes in macrophages, is upregulated by TLR signaling, and is required for CCL2 chemokine production and macrophage recruitment during innate immune responses, establishing the channel's physiological role in immunity.

   Evidence TRPML2-knockout mouse challenged with LPS and live bacteria; immunofluorescence localization, qRT-PCR, and in vivo macrophage recruitment assays

   PMID:26432893

   Open questions at the time

   • Mechanism linking channel ion flux to CCL2 transcription/secretion not delineated
   • Which TLR-downstream signaling pathway upregulates TRPML2 not identified
   • Whether TRPML2 regulates other chemokines beyond CCL2 not tested
5. 2018 High

   Using the isoform-selective agonist ML2-SA1 and endolysosomal patch-clamp demonstrated that TRPML2 directly mediates CCL2 vesicular trafficking and secretion through the early/recycling endosomal pathway, connecting channel activity to the cargo-specific secretory mechanism.

   Evidence Endolysosomal patch-clamp electrophysiology with ML2-SA1, ELISA for CCL2 release, macrophage migration assays, TRPML2-KO controls

   PMID:30479274

   Open questions at the time

   • Whether TRPML2 acts via Ca²⁺ release, membrane fusion, or vesicle budding not resolved
   • Other cargo trafficked by TRPML2 not systematically catalogued
6. 2019 High

   Crystal structures of the TRPML2 extracytosolic/luminal domain at two pH values revealed a tetrameric architecture with a Ca²⁺-binding pre-pore loop whose affinity is abolished at low pH, providing the first structural explanation for pH-dependent gating.

   Evidence X-ray crystallography at 2.0 Å (pH 6.5) and 2.95 Å (pH 4.5), ITC for Ca²⁺ binding, native mass spectrometry

   PMID:31178222

   Open questions at the time

   • Full-length channel structure in open/conducting state not available at this point
   • How Ca²⁺ binding at the ELD transduces to pore gating not determined
7. 2021 High

   Cryo-EM of full-length mouse TRPML2 in lipid nanodiscs at 3.14 Å captured the channel in an inactive apo conformation and revealed unique features of the voltage sensor-like domain, providing the first complete structural framework for the channel.

   Evidence Cryo-EM in lipid nanodiscs at pH 7.4

   PMID:34915027

   Open questions at the time

   • Active/open-state structure not captured
   • Agonist-bound or PI-bound structures not determined
   • Mechanism of selectivity among divalent cations not structurally explained
8. 2020 High

   Discovery that TRPML2 is a hypotonicity/mechanosensitive channel dependent on its phosphoinositide-binding pocket (L314) linked the channel's lipid-sensing capability to regulation of the fast-recycling endosomal pathway in immune cells.

   Evidence Endolysosomal patch-clamp with hypotonicity stimulation, L314R mutagenesis, recycling assays in immune cells

   PMID:33177082

   Open questions at the time

   • Identity of the endogenous phosphoinositide species activating TRPML2 not confirmed
   • Whether mechanosensitivity operates in non-immune cell types not tested
   • Structural basis of mechanosensitive gating not resolved
9. 2021 Medium

   MCOLN2 was shown to promote IL-1β production, NF-κB activation, and prostate cancer cell proliferation and invasion, extending the channel's signaling repertoire beyond chemokine trafficking to inflammatory cytokine pathways.

   Evidence siRNA knockdown and overexpression in prostate cancer cell lines, xenograft model, cytokine array, NF-κB luciferase reporter assay

   PMID:34548638

   Open questions at the time

   • Mechanism linking TRPML2 ion flux to NF-κB activation not identified
   • Relevance to primary immune cells not established
   • Single-lab finding without independent replication
10. 2023 High

    Direct measurement of Mg²⁺ currents through TRPML2 and human GWAS linking MCOLN2 variants to intracellular S. Typhi replication established a nutritional immunity function: TRPML2 depletes endolysosomal Mg²⁺ to restrict bacterial growth.

    Evidence Endolysosomal patch-clamp for Mg²⁺ currents, GWAS in cellular infection model, S. Typhi transcriptomics, Mg²⁺ manipulation experiments

    PMID:37228749

    Open questions at the time

    • Whether Mg²⁺ restriction applies to other intracellular pathogens not shown
    • Relative contribution of TRPML2 vs other transporters to endolysosomal Mg²⁺ not quantified
    • In vivo validation of MCOLN2 variants in S. Typhi susceptibility not performed
11. 2026 Medium

    Sphingomyelin accumulation was identified as an endogenous lipid inhibitor of TRPML2-mediated lysosomal Ca²⁺ release; this inhibition sensitizes lysosomes to membrane permeabilization, providing a mechanistic basis for obinutuzumab-induced direct cell death.

    Evidence Imaging, genetic knockdown, SMase rescue, Ca²⁺ measurement, and lysosomal membrane permeabilization assays in B-cell lymphoma models

    PMID:41634107

    Open questions at the time

    • Direct binding site for sphingomyelin on TRPML2 not mapped
    • Whether SM inhibition is specific to TRPML2 or also affects TRPML1/3 not fully resolved
    • Clinical relevance of TRPML2 inhibition in obinutuzumab therapy not validated in patients

• Key unresolved questions include the structural basis of TRPML2 in an open/agonist-bound state, the precise signaling intermediates connecting TRPML2 ion flux to NF-κB activation and chemokine vesicle fusion, and the full spectrum of pathogens subject to TRPML2-mediated nutritional immunity.
• No agonist-bound or open-state structure available
• Signaling cascade from TRPML2 Ca²⁺/Mg²⁺ flux to NF-κB not mapped
• Comprehensive in vivo phenotyping of TRPML2-KO mice in diverse infection models lacking